Unternehmensübersicht
Adagio Medical Holdings, Inc. operates as a developmental stage medical device company dedicated to the research and development of ablation technologies specifically designed for the treatment of cardiac arrhythmias. The firm provides therapeutic solutions for various cardiac rhythm disorders, including atrial fibrillation, atrial flutter, and ventricular arrhythmias, targeting a specialized niche within the medical device sector. This company is classified under the Healthcare industry, a domain characterized by high regulatory standards and significant reliance on innovation to drive commercialization. Currently, the enterprise is valued at a market capitalization of $31.32M, reflecting its position as a small-cap entity with limited operational history or scale. The absence of reported annual revenue and employee data further underscores the developmental nature of the business, indicating that the firm is likely in an early phase of product lifecycle where capital allocation prioritizes R&D and market entry over immediate profit generation or large-scale manufacturing expansion.
Finanzielle Gesundheit
The company reports a net income of $-25,084,000 and an EBITDA of $-20,920,000 over the trailing twelve-month period, while revenue figures are not disclosed. The significant discrepancy between the reported net income and the negative EBITDA suggests a substantial tax benefit or specific accounting adjustments that temporarily improved the bottom line relative to operational cash earnings, yet the fundamental operational profitability remains absent. Free cash flow stands at $-11,178,500, indicating that the company is currently burning cash, which limits its financial flexibility and necessitates reliance on external financing or existing cash reserves to fund ongoing operations and development activities. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, a metric that typically signifies either a lack of recognized revenue in the financial statements or an inability to cover direct and indirect costs with the current revenue structure. Regarding balance sheet strength, the company holds $17.11M in cash against $21.76M in debt, resulting in a debt-to-equity ratio of 175.44, which indicates a highly leveraged position where equity is minimal relative to obligations. Despite the high leverage, the current ratio is reported at 2.44, suggesting that the company maintains sufficient liquid assets to cover its short-term liabilities, although this liquidity may be constrained by the need to service debt and fund operations. Return on Equity is calculated at -155.3% and Return on Assets at -29.8%, metrics that reveal that management has not yet generated positive returns on shareholder capital or the asset base, a common characteristic for pre-revenue or early-stage biotech and medical device firms.
Bewertungsanalyse
The P/E Ratio (TTM) is listed as N/A due to the lack of positive net income, while the Forward P/E is reported at -1.33, implying that analysts or data providers project continued negative earnings in the near future. The price-to-book ratio stands at 2.53, indicating that the market values the company at a premium of 153% above its book value, a valuation often seen in firms with intangible assets or growth potential that are not yet reflected on the balance sheet. The Price to Sales metric is N/A, and the EV/EBITDA ratio is -1.72, suggesting that traditional valuation multiples based on earnings or sales are currently inapplicable or indicate negative enterprise value characteristics relative to earnings. The stock has traded between a 52-week low of $0.73 and a 52-week high of $2.87; without the specific current share price in the provided facts, the relative trading position cannot be calculated, but the wide range of $2.14 demonstrates significant intrayear volatility. The Beta value is recorded at 0.04, which is exceptionally low and suggests that the stock price exhibits minimal volatility relative to the broader market, potentially due to low trading volume or a lack of correlation with general market movements.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, which precludes any calculation of growth percentages or comparison of earnings velocity against revenue expansion. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the firm retains all generated earnings, if any, and reinvests capital directly into research and development, clinical trials, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile is defined by the absence of historical revenue data and a lack of dividend income, focusing the return on investment potential entirely on the future success of its ablation technology platform and its ability to transition from a developmental stage to a profitable commercial entity.